Skip to content

Press Releases

You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.

Asarina Pharma AB (publ) Year-end Report 2021 released

Peter Nordkild, CEO: “We enter the new financial year with renewed energy and optimism after Region Hovedstaden finally signed the required papers for our clinical test sites in Copenhagen, and we achieved ‘First Patient First Visit’ on 16 February in our phase IIa clinical study in Tourette syndrome. We are now moving ahead confidently in…

Full PDF

First patient in for landmark Tourette Syndrome study

(Stockholm, 16 February, 2022.) Asarina Pharma announces today that ‘First Patient First Visit’ has taken place in its phase IIa clinical study in Tourette syndrome at Bispebjerg University Hospital, Copenhagen. The Asarina compound being trialled, Sepranolone, is an endogenous neurosteroid that has already demonstrated a strong safety profile in previous clinical studies. In preclinical studies…

Full PDF

Asarina Pharma receives final approval for landmark phase IIa Tourette study

(Stockholm, Sweden, 22 December, 2021.) The Capital Region of Denmark (Region Hovedstaden) has now given official approval to Asarina Pharma to begin its phase IIa study in Tourette, following a four-month delay due to an administrative backlog

Full PDF

Asarina Pharma AB (publ) Q3 Report 2021 released

Asarina Pharma CEO Peter Nordkild: “While we made progress in several areas during Q3 2021, it was frustrating for us that our phase IIa study in Tourette Syndrome was delayed. We now expect our first patients to be included in the Study in December.”

Full PDF

PMDD Phase IIb study, including post-hoc analysis showing ‘significant treatment effect’, published in Journal of Psychoneuroendocrinology

(Stockholm, 28 September 2021.) The publication of Asarina Pharma’s phase IIb study, including a post hoc analysis into Sepranolone for PMDD (Premenstrual dysphoric disorder), demonstrates that Sepranolone in a 10 mg dose did have a significant treatment effect compared with placebo, when examined in an extended 9-day analysis of symptom reduction. Senior PMDD Key Opinion…

Full PDF
Consultant Neurologist Dr. Heidi Biernat, Head of the Tourette Clinic at Copenhagen’s Bispebjerg University Hospital and Principal Investigator in...
The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (“the Company”) on...
The Phase IIa results demonstrated that Sepranolone could become the first-line pharma treatment for Tourette as it showed competitive tic reduction and...
Asarina Pharma AB (publ) releases Annual Report 2022 2023-04-28 20:30 Regulatory Annual
The full Annual Report 2022 is available on: https://asarinapharma.com/investors/financial-reports/ Research and Development: This year, Asarina’s...
NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. Right to participate...
THE STUDY: This was an open label, dual center, add-on study, randomizing 28 Tourette Syndrome patients, 20 males/8 females, 3 adolescents/25 adults between...
Asarina Pharma AB (publ) releases Year-End Report 2022 2023-02-27 08:30 Regulatory Interim
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS Recruitment completed: patient recruitment to Phase IIa study in Tourette completed in October 2022. A total of...
A total of 28 patients took part in the study: a ‘control group’ of 9 patients who received their standard treatment, plus an ‘active...
Enrollment of adult patients started at the Bispebjerg University Hospital in Copenhagen in February 2022, while teenage patients have been enrolled at...
A new study, the fourth and most comprehensive in a series of four (1), reconfirms that acute stress increases the overproduction of the powerful neurosteroid...